Clinical Predictive Value of Serum Angiogenic Factor in Patients with Osteosarcoma

被引:10
作者
Chen, Zhe [1 ,2 ]
Chen, Qi-Xin [1 ]
Hou, Zhao-Yang [2 ]
Hu, Jiong [2 ]
Cao, Yan-Guang [2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Orthopaed, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China
关键词
Osteosarcoma; angiogenic facor; microvessel density; ENDOTHELIAL GROWTH-FACTOR; FACTOR ENDOSTATIN; VEGF; CHEMOTHERAPY; EXPRESSION; EFFICACY; THERAPY; SAFETY;
D O I
10.7314/APJCP.2012.13.9.4823
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To explore serum angiogenic factor expression in patients with osteosarcoma and its relationship with metastasis. Methods: Immunohistochemistry was used to test the expression of CD34 and FVIII-Rag in osteosarcoma tissues of 36 patients (osteosarcoma group) and microvessel density (MVD) was also recorded. In addition, ELISA was used to test the level of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-beta 1 (TGF-beta 1) and endostatin (ES) in the osteosarcoma group and in a control group. Results: VEGF and ES level were significantly higher than in the control group before operation (P < 0.01), VEGF, bFGF and TGF-beta 1 correlating with the ES level (P < 0.01). Serum VEGF and ES levels of osteosarcoma patients before surgery were closely related to relapse and metastasis; moreover, serum VEGF increased with MVD (P < 0.01). Postoperative VEGF and ES levels were lower than the preoperation values (P < 0.01); ES level in relapse group was significantly higher than that of the non-relapse group (P < 0.01). Conclusion: Preoperative serum VEGF and postoperative ES levels have great predictive value with regard to relapse of osteosarcoma patients.
引用
收藏
页码:4823 / 4826
页数:4
相关论文
共 23 条
[1]  
[Anonymous], ASIAN PAC J CANC PRE, V12, P1717
[2]  
Balu S, 2012, ROM J MORPHOL EMBRYO, V53, P479
[3]   Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors [J].
Dirkx, Anita E. M. ;
Egbrink, Mirjam G. A. oude ;
Castermans, Karolien ;
van der Schaft, Daisy W. J. ;
Thijssen, Victor L. J. L. ;
Dings, Ruud P. M. ;
Kwee, Lucy ;
Mayo, Kevin H. ;
Wagstaff, John ;
Steege, Jessica C. A. Bouma-ter ;
Griffioen, Arjan W. .
FASEB JOURNAL, 2006, 20 (06) :621-630
[4]  
Gao LL, 2011, ASIAN PAC J CANCER P, V12, P77
[5]   Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. [J].
Hlobilkova, A. ;
Ehrmann, J. ;
Knizetova, P. ;
Krejci, V. ;
Kalita, O. ;
Kolar, Z. .
NEOPLASMA, 2009, 56 (04) :284-290
[6]   Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect [J].
Kasuya, Kazuhiko ;
Nagakawa, Yuichi ;
Suzuki, Minako ;
Tanaka, Hiroaki ;
Ohta, Hiroshi ;
Itoi, Takao ;
Tsuchida, Akihiko .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, 2 (06) :1047-1052
[7]   Anti-angiogenic factor endostatin in osteosarcoma [J].
Kim, Hyun-Soo ;
Lim, Sung-Jig ;
Park, Yong-Koo .
APMIS, 2009, 117 (10) :716-723
[8]   Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma? [J].
Lee, Jun Ah ;
Ko, Yunmi ;
Kim, Dong Ho ;
Lim, Jung Sub ;
Kong, Chang-Bae ;
Cho, Wan Hyeong ;
Jeon, Dae-Geun ;
Lee, Soo-Yong ;
Koh, Jae-Soo .
CANCER RESEARCH AND TREATMENT, 2012, 44 (03) :202-209
[9]  
Li CG, 2011, ASIAN PAC J CANCER P, V12, P2477
[10]  
Li CG, 2011, ASIAN PAC J CANCER P, V12, P487